Division of Cardiovascular Surgery, Toronto General Hospital Research Institute, University Health Network , Toronto, Ontario , Canada.
Division of Cardiac Surgery, Department of Surgery, University of Toronto , Toronto, Ontario , Canada.
Am J Physiol Heart Circ Physiol. 2018 Oct 1;315(4):H733-H744. doi: 10.1152/ajpheart.00100.2018. Epub 2018 Jun 27.
Cell therapy has received significant attention as a therapeutic approach to restore cardiac function after myocardial infarction. Accumulating evidence supports that beneficial effects observed with cell therapy are due to paracrine secretion of multiple factors from transplanted cells, which alter the tissue microenvironment and orchestrate cardiac repair processes. Of these paracrine factors, extracellular vesicles (EVs) have emerged as a key effector of cell therapy. EVs regulate cellular function through the transfer of cargo, such as microRNAs and proteins, which act on multiple biological pathways within recipient cells. These discoveries have led to the development of cell-free therapies using EVs to improve cardiac repair after a myocardial infarction. Here, we present an overview of the current use of EVs to enhance cardiac repair after myocardial infarction. We also discuss the emerging use of EVs for rejuvenation-based therapies. Finally, future directions for the use of EVs as therapeutic agents for cardiac regenerative medicine are also discussed.
细胞疗法作为一种治疗心肌梗死后恢复心脏功能的方法受到了广泛关注。越来越多的证据表明,细胞疗法的有益效果是由于移植细胞分泌的多种因子的旁分泌作用,这些因子改变了组织微环境并协调心脏修复过程。在这些旁分泌因子中,细胞外囊泡(EVs)已成为细胞疗法的关键效应因子。EVs 通过传递货物(如 microRNAs 和蛋白质)来调节细胞功能,这些货物作用于受体细胞内的多个生物学途径。这些发现导致了使用 EVs 进行无细胞治疗的发展,以改善心肌梗死后的心脏修复。在这里,我们介绍了目前使用 EVs 增强心肌梗死后心脏修复的情况。我们还讨论了 EVs 在基于再生的治疗中的新兴用途。最后,还讨论了将 EVs 用作心脏再生医学治疗剂的未来方向。